OncoMatch/Clinical Trials/NCT07014319

Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies

Is NCT07014319 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Maribavir for cytomegalovirus (cmv).

Phase 2RecruitingSeoul National University HospitalNCT07014319Data as of May 2026

Treatment: Maribavir — This is an open-label, single arm, multicenter study to evaluate the feasibility of maribavir treatment in multiple myeloma and lymphoma patients undergoing bispecific antibody treatment and experiencing treatment emergent CMV events

Check if I qualify

Extracted eligibility criteria

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Must have received: bispecific antibody (Teclistamab, Elranatamab, Talquetamab, Cevostamab, ABBV383, Mosunetuzumab, Glofitamab, Epcoritamab, Odronextamab)

receiving one of the following bispecific antibodies: Multiple Myeloma: Teclistamab, Elranatamab, Talquetamab, Cevostamab, ABBV383 Lymphomas: Mosunetuzumab, Glofitamab, Epcoritamab, Odronextamab

Lab requirements

Kidney function

Creatinine clearance <10 mL/min or requiring dialysis (Cockcroft-Gault formula used)

Liver function

AST or ALT >5 × ULN, total bilirubin >3 × ULN (except Gilbert's syndrome) excluded

Creatinine clearance <10 mL/min or requiring dialysis...AST or ALT >5 × ULN...Total bilirubin >3 × ULN (except Gilbert's syndrome)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify